OakChart

Profound Medical Corp

PROFHealthcare·Medical Devices·Canada·Micro·NASD·Nov 11 • 5:06 AM ET

7.66-0.02 (-0.26%)
2026-11-11 15:15 CET
Market cap
281.29 USD m
Revenue, TTM
23.63 USD m
Net income, TTM
-32.49 USD m
Free cash flow, TTM
-31.00 USD m
EPS diluted, TTM
-0.93
P/E
-
Compare

Price

PROF against its 20, 50 and 200-day averages
2050200beatmiss
6.007.008.001.5M3.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PROFclose 7.6620-day 6.4150-day 6.28200-day 6.647.66

14.4% under 8.95 on 13 Jan 2026. Last 15 sessions, 47.5% high to low

Profile

PROF
52-week range, 69% of the way up
4.808.95

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm's product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.

Employees162
IPOJun 09, 2016
Beta0.74
ATR, 14d0.45
Rel volume0.00
Short float4.45%
Insider own3.05%
Inst own45.61%

Snapshot

6 groups

Valuation

Index-
Market Cap280.59M
Enterprise Value254.61M
Income-32.49M
Sales23.63M
Book/sh1.16
Cash/sh0.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees162
IPOJun 09, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S11.87
P/B6.60
P/C8.42
P/FCF-
EV/EBITDA-
EV/Sales10.77
Quick Ratio3.70
Current Ratio4.54
Debt/Eq0.17
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.93
EPS next Y-0.62
EPS next Q-0.23
EPS this Y38.77%
EPS next Y27.99%
EPS next 5Y61.57%
EPS past 3/5Y-0.76% -2.41%
Sales past 3/5Y34.06% 17.12%
EPS Y/Y TTM30.10%
Sales Y/Y TTM65.25%
EPS Q/Q20.30%
Sales Q/Q85.86%
EarningsNov 05 AMC
EPS/Sales Surpr.-9.37% 11.45%

Ownership

Insider Own3.05%
Insider Trans0.00%
Inst Own45.61%
Inst Trans0.20%
ROA-64.68%
ROE-87.04%
ROIC-71.79%
Gross Margin73.86%
Oper. Margin-145.08%
Profit Margin-137.51%
SMA2019.53%
SMA5021.98%
SMA20015.31%
Trades-

Technical

Shs Outstand36.63M
Shs Float35.51M
Short Float4.45%
Short Ratio7.59
Short Interest1.58M
52W High8.95 -14.41%
52W Low4.80 59.58%
Volatility10.14% 7.13%
ATR (14)0.45
RSI (14)69.05
Beta0.74
Rel Volume0.00
Avg Volume208.35K
Volume45

Performance

Perf Week6.98%
Perf Month9.27%
Perf Quarter14.84%
Perf Half Y7.89%
Perf YTD-2.67%
Perf Year19.22%
Perf 3Y-13.93%
Perf 5Y-35.58%
Perf 10Y9.82%
Recom1.00
Target Price11.28
Prev Close7.68
Price7.66
Change %-0.26%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Jul 27, 2026UpgradeRRaymond JamesOutperform → Strong Buy$11+43.6%
Jul 23, 2024InitiatedLLake StreetBuy$16.50+115.4%
Jul 16, 2024UpgradeSStifelHold → Buy$9 → $12+56.7%
Nov 28, 2023InitiatedSStifelHold$11+43.6%
Aug 04, 2023DowngradeRRaymond JamesStrong Buy → Outperform$20 → $200+2,511.0%
Mar 21, 2023DowngradeJJefferiesBuy → Hold$5.50 → $10+30.5%
Sep 15, 2020InitiatedJJefferiesBuy

Peers

Mkt cap
TickerCompanyMkt cap
PRCTProcept BioRobotics Corp1.33B
CLPTClearPoint Neuro Inc292.38M
ANGOAngiodynamic Inc507.18M
ICCMIcecure Medical Ltd2.74M
HYPRHyperfine Inc73.58M
TLSITriSalus Life Sciences Inc175.49M
BSXBoston Scientific Corp64.05B
TFXTeleflex Incorporated6.06B
APYXApyx Medical Corp123.42M
ISRGIntuitive Surgical Inc155.64B

Held by

AUM
TickerCompanyAUM
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
DFICDimensional International Core Equity 2 ETF-

News

latest 14 of 206
  • Profound Medical to Participate in the Stifel 2026 Healthcare Conference (GlobeNewswire)
  • Profound Medical Posts Record Revenue But Misses On EPS As Shipment Timing Flatters Growth And Cash Keeps Shrinking (Earnings Whispers)
  • Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth (GlobeNewswire)
  • Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO Sales Channels and Drive Recurring Revenue Growth (GlobeNewswire) +12.12%
  • Profound Medical Must Prove Its Slipped Shipment Was Timing, Not A Demand Problem (Earnings Whispers)
  • Loading…
  • Emmy-Award Winning Television Host Montel Williams to Join Next 'Let's Huddle' Webinar (GlobeNewswire)
  • TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity (GlobeNewswire) -5.56%
  • Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment Education (InvestorsHub)
  • Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care (GlobeNewswire)
  • Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue (GlobeNewswire) -6.58% +21.65%
  • Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference (GlobeNewswire)
  • Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President (GlobeNewswire)
  • Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full 'TULSA Days' (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.210-0.192-0.2109.838.825
2026Q22026-08-06-0.260-0.243-0.2622.484.754
2026Q12026-05-07-0.190-0.250-0.1945.344.855
2025Q42026-03-05-0.270-0.273-0.2665.987.673
2025Q32025-11-13-0.260-0.372-0.2655.294.985
2025Q22025-08-14-0.520-0.370-0.5222.213.254
2025Q12025-05-08-0.360-0.283-0.3572.623.334
2024Q42025-03-06-0.200-0.323-0.1924.184.234
2024Q32024-11-07-0.380-0.300-0.3822.833.005
2024Q22024-08-08-0.280-0.282-0.2832.232.646
2024Q12024-05-09-0.260-0.298-0.2551.912.444
2023Q42024-03-07-0.420-0.312-0.4172.001.977
2023Q32023-11-02-0.260-0.339-0.2621.732.206
2023Q22023-08-09-0.350-0.351-0.3481.602.137
2023Q12023-05-10-0.320-0.353-0.3221.862.126
2022Q42023-03-07-0.460-0.373-0.4561.302.677

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.359-1.391-1.3714.134.19
2020FY-1.250-1.076-1.2507.306.37
2021FY-1.500-1.274-1.5006.879.56
2022FY-1.380-1.293-1.3766.708.09
2023FY-1.350-1.230-1.3377.207.11
2024FY-1.120-1.243-1.12310.6811.23
2025FY-1.410-1.365-1.41016.1017.57
2026FY--0.863--25.82
2027FY--0.622--42.83
2028FY--0.080--63.14
2029FY-0.710--105.36
2030FY-1.070--139.21

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-065128.447.4010.50
2026Q4S2026-10-215029.127.4011.10
2026Q4S2026-10-075329.127.4011.10
2026Q4S2026-10-065319.427.4011.10
2026Q4S2026-09-0953010.109.0011.10
2026Q4S2026-08-074309.939.0011.10
2026Q4S2026-08-054008.688.009.00
2026Q4S2026-07-224018.688.009.00
2026Q4S2026-06-274048.688.009.00
2026Q4S2026-06-025048.908.009.78
2026Q4S2026-05-225058.908.009.78
2026Q4S2026-05-085059.168.0010.30
2026Q4S2026-03-1952210.389.7810.80
2026Q4S2026-03-1352110.5010.3010.80

Estimate history

EPS, annual-2.388-1.596-1.371-1.25-1.5-1.376-1.337-1.123-1.408-0.934
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.382-0.192-0.357-0.522-0.265-0.266-0.194-0.262-0.211
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual3.7792.0084.1667.3046.8736.6817.19910.6816.09823.63
Period201720182019202020212022202320242025TTM
Sales, quarterly2.8324.1772.6212.2115.2895.9775.3372.4839.83
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual7.31210.80511.85320.20920.77620.87921.37130.0436.29436.627
Period201720182019202020212022202320242025MRQ
Shares, quarterly24.66230.0430.05330.05330.19436.29436.33836.53336.627
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue23.6316.1010.687.206.686.877.304.172.01
Cost of Goods Sold Incl. D&A6.184.713.642.893.663.923.831.781.38
Gross Profit17.4511.397.044.313.022.953.472.390.63
Selling, General and Administrative Excl. Other51.7352.6540.1032.9632.6233.2423.0317.2816.40
Research and Development20.9920.6016.9714.4214.6915.2810.239.398.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-34.28-41.25-33.06-28.65-29.60-30.29-19.55-14.90-15.77
Interest Expense---0.920.170.070.541.040.79
Unusual Expense0.000.000.000.002.80-0.29-0.05-0.61-0.33
Net Income Before Taxes-32.39-42.32-27.82-28.45-28.38-30.59-21.89-15.07-16.03
Income Taxes0.100.25-0.00-0.130.290.11-0.270.15-0.01
Consolidated Net Income-32.49-42.57-27.82-28.32-28.67-30.70-21.62-15.22-16.02
Net Income From Continuing Operations-32.49-42.57-27.82-28.32-28.67-30.70-21.62-15.22-16.02
Net Income-32.49-42.57-27.82-28.32-28.67-30.70-21.62-15.22-16.02
EPS (Recurring)-0.89-1.41-1.12-1.34-1.28-1.51-1.25-1.41-1.62
EPS (Basic, Before Extraordinaries)-0.93-1.41-1.12-1.34-1.38-1.50-1.25-1.37-1.60
EPS (Diluted)-0.93-1.41-1.12-1.34-1.38-1.50-1.25-1.37-1.60
EBITDA-33.80-40.69-32.13-27.72-28.00-28.41-18.02-13.38-14.47
Non-Operating Income (Expense)1.89-1.065.240.204.19-0.53-1.840.250.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.044.342.042.703.605.302.220.930.62
Price To Sales Ratio9.0914.7617.4124.7733.3233.6148.6830.3020.14
Gross Margin73.8670.7765.8959.9045.2242.9547.5657.2731.46
Operating Margin-145.08-256.27-309.57-397.99-443.08-440.72-267.73-357.63-785.27
Net Margin-137.51-264.44-260.45-393.43-429.11-446.66-296.03-365.30-797.88
Shares Outstanding36.6336.2930.0421.3720.8820.7820.2111.8510.81
Market Capitalization281.29281.29225.51180.50227.34233.24403.51129.7945.38

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue9.832.485.345.985.292.212.624.18
Cost of Goods Sold Incl. D&A2.150.541.511.991.360.590.771.21
Gross Profit7.681.953.833.993.931.621.852.96
Selling, General and Administrative Excl. Other15.5013.0111.8511.3612.8415.4213.0211.31
Research and Development5.815.655.264.275.426.104.814.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.82-11.07-8.02-7.37-8.91-13.81-11.17-8.34
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-7.73-9.49-7.03-8.15-7.86-15.63-10.68-5.18
Income Taxes-0.000.060.030.030.120.060.04-0.24
Consolidated Net Income-7.72-9.54-7.05-8.18-7.98-15.70-10.72-4.95
Net Income From Continuing Operations-7.72-9.54-7.05-8.18-7.98-15.70-10.72-4.95
Net Income-7.72-9.54-7.05-8.18-7.98-15.70-10.72-4.95
EPS (Recurring)-0.21-0.26-0.19-0.27-0.26-0.52-0.36-0.19
EPS (Basic, Before Extraordinaries)-0.21-0.26-0.19-0.27-0.27-0.52-0.36-0.19
EPS (Diluted)-0.21-0.26-0.19-0.27-0.27-0.52-0.36-0.19
EBITDA-7.69-10.93-7.92-7.26-8.77-13.66-11.00-8.28
Non-Operating Income (Expense)0.101.580.99-0.781.06-1.820.483.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.690.831.321.231.150.78-
Price To Sales Ratio9.0912.6612.3015.0010.2915.0714.4517.35
Gross Margin78.1378.4171.8066.7774.3273.1870.7070.94
Operating Margin-79.56-445.67-150.29-123.29-168.52-624.42-426.02-199.76
Net Margin-78.56-384.21-132.15-136.77-150.82-709.86-409.16-118.41
Shares Outstanding36.6336.5336.3436.2930.1930.0530.0530.04
Market Capitalization281.29241.65235.18237.62146.96177.31174.83225.51

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments59.7254.9126.2146.5267.1583.9114.8222.478.86
Short Term Receivables7.207.047.296.341.417.433.312.323.58
Inventories8.245.806.997.947.415.333.672.661.14
Other Current Assets0.931.311.411.221.151.071.030.320.46
Total Current Assets76.0969.0641.9062.0277.1297.7422.8427.7614.05
Net Property, Plant & Equipment0.880.821.571.721.902.282.220.881.38
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable0.30--0.003.62----
Intangible Assets0.140.260.490.684.124.585.045.436.82
Deferred Tax Assets63.4653.6846.01------
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets140.87123.8389.9664.4286.78104.6030.1134.0822.25
Short Term Debt Incl. Current Port. of LT Debt0.211.992.360.760.250.314.170.983.81
Accounts Payable1.561.320.862.033.183.383.032.864.06
Income Tax Payable0.04-0.000.300.000.010.010.220.06
Other Current Liabilities4.263.253.141.090.721.101.031.710.64
Total Current Liabilities6.086.576.374.184.164.818.245.778.56
Long Term Debt4.503.135.507.471.131.366.827.770.38
Provision for Risks Charges0.000.000.000.000.000.000.010.040.79
Deferred Tax Liabilities63.4053.5946.07------
Other Liabilities0.470.120.800.760.881.080.641.011.24
Total Liabilities74.4463.4158.7412.426.167.2515.7114.5910.96
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity66.4360.4231.2252.0080.6297.3514.3919.5011.29
Total Shareholders Equity66.4360.4231.2252.0080.6297.3514.3919.5011.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity66.4360.4231.2252.0080.6297.3514.3919.5011.29
Total Liabilities & Stockholders Equity140.87123.8389.9664.4286.78104.6030.1134.0822.25
Book Value Per Share1.832.011.462.493.884.821.211.801.54
Tangible Book Value Per Share1.832.001.442.463.684.590.791.300.61
Full-Time Employees162142131-14610975-64
Price to Book Ratio6.625.964.703.782.894.339.022.333.25
Return on Assets-32.16-33.17-36.69-37.92-32.08-32.10-47.41-56.87-72.65
Return on Equity-67.12-60.73-68.06-43.23-34.50-38.70-89.81-104.08-129.77
Return on Invested Capital-60.01-43.77-77.12-48.21-37.55-21.90-71.73-58.75-124.33
Quick Ratio11.179.645.4812.9216.7819.222.334.351.51
Current Ratio12.5210.526.5814.8218.5620.322.774.811.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-31.80-42.57-27.82-28.32-28.67-30.70-21.62-15.22-16.02
Depreciation0.470.560.940.931.601.881.541.521.29
Other Funds (Non Cash)3.645.522.844.256.897.344.151.681.31
Funds from Operations-27.69-36.49-24.04-23.15-20.17-21.48-15.94-12.02-13.42
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.14-1.710.590.54-5.63-0.88-4.64-3.08-0.69
Income Taxes Payable0.010.07-0.15-0.240.31-0.010.00-0.210.17
Cash from Operating Activities-30.83-38.21-23.45-22.61-25.80-22.36-20.57-15.10-14.11
Capital Expenditures-0.24-0.240.000.000.00-0.59-0.35-0.190.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00-
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.24-0.240.000.000.00-0.59-0.35-0.190.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock42.5742.4462.152.670.266.4397.257.9024.79
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock42.5742.4462.152.670.266.4397.257.9024.79
Proceedsfrom Stock Options42.5342.4462.110.000.000.0079.097.9024.71
Issuance or Reduction of Debt, Net-1.01-1.31-7.46-0.917.080.00-9.32-0.014.56
Change in Long Term Debt-1.01-1.31-7.46-0.917.080.00-9.32-0.014.56
Issuance of Long Term Debt0.000.000.000.007.120.000.000.009.08
Reduction of Long Term Debt-1.01-1.31-7.46-0.91-0.040.00-9.32-0.01-4.51
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.10-0.21-1.00-0.13
Other Financing Activities Uses0.000.000.000.000.00-0.10-0.21-1.00-0.13
Cash from Financing Activities41.5541.1454.701.767.035.9587.436.6429.22
Exchange Rate Effect-1.222.12-2.540.55-1.870.242.60--
Net Change in Cash9.264.8128.70-20.30-20.64-16.7669.11-8.6415.11
Free Cash Flow-31.00-38.38-23.45-22.61-25.80-22.39-20.57-15.10-14.11
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments33.3438.2750.3059.7224.8335.20
Short Term Receivables10.999.619.427.208.174.90
Inventories10.2410.469.008.248.348.35
Other Current Assets0.250.520.810.930.200.36
Total Current Assets54.8358.8669.5376.0941.5248.81
Net Property, Plant & Equipment3.123.323.580.880.580.58
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.120.120.130.140.120.17
Deferred Tax Assets0.090.080.0763.460.080.10
Other Assets0.000.000.000.000.000.00
Total Assets58.1562.3873.46140.8742.3049.67
Short Term Debt Incl. Current Port. of LT Debt4.624.634.570.214.760.28
Accounts Payable1.050.952.141.560.720.95
Income Tax Payable0.080.060.040.040.06-
Other Current Liabilities6.323.473.854.264.414.50
Total Current Liabilities12.069.1110.616.089.945.72
Long Term Debt2.742.752.894.500.004.53
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---63.40--
Other Liabilities0.840.710.530.470.220.15
Total Liabilities15.6412.5814.0374.4410.1610.41
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity42.5149.8159.4266.4332.1439.26
Total Shareholders Equity42.5149.8159.4266.4332.1439.26
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity42.5149.8159.4266.4332.1439.26
Total Liabilities & Stockholders Equity58.1562.3873.46140.8742.3049.67
Book Value Per Share1.161.361.641.831.061.31
Tangible Book Value Per Share1.161.361.631.831.061.30
Full-Time Employees---162--
Price to Book Ratio6.624.073.547.393.743.49
Return on Assets-64.68-58.45-57.92-32.17-93.07-81.98
Return on Equity-87.04-73.53-70.59-67.12-124.49-104.23
Return on Invested Capital-17.06-18.15-11.32-11.52-24.82-35.84
Quick Ratio3.705.315.7111.173.347.07
Current Ratio4.546.466.5612.524.188.53

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.55-9.46-7.05-7.74-8.04-16.16
Depreciation0.130.130.100.100.150.15
Other Funds (Non Cash)0.290.921.101.331.691.49
Funds from Operations-7.12-8.41-5.85-6.31-6.20-14.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.28-2.83-2.730.15-3.510.39
Income Taxes Payable0.000.01-0.00-0.000.08-0.01
Cash from Operating Activities-4.84-11.25-8.58-6.16-9.71-14.13
Capital Expenditures0.000.000.00-0.240.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.240.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.040.000.0042.530.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.040.000.0042.530.000.00
Proceedsfrom Stock Options0.000.000.0042.530.000.00
Issuance or Reduction of Debt, Net0.000.000.00-1.010.00-0.01
Change in Long Term Debt0.000.000.00-1.010.00-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-1.010.00-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.040.000.0041.520.00-0.01
Exchange Rate Effect0.05-0.68-0.850.25-0.772.55
Net Change in Cash-4.75-11.92-9.4335.37-10.48-11.59
Free Cash Flow-4.84-11.25-8.58-6.34-9.71-14.13

Revenue breakdown

Capital Equipment2024: 2.44M 2025: 6.37M
Recurring - Non-Capital2024: 8.24M 2025: 9.73M
Canada2024: 2.44M 2025: 3.08M
Germany2024: 891.00K 2025: 773.00K
United States2024: 7.35M 2025: 12.25M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.45%1.6M35.5M190.30K
2026-10-154.40%1.6M35.4M185.13K
2026-09-304.19%1.5M35.4M118.73K
2026-09-154.44%1.6M35.4M107.91K
2026-08-314.57%1.6M35.5M95.53K
2026-08-145.19%1.8M35.5M85.66K
2026-07-315.09%1.8M35.5M82.22K
2026-07-155.25%1.9M35.3M74.83K
2026-06-305.87%2.1M35.3M75.64K
2026-06-156.06%2.1M35.4M120.03K
2026-05-296.23%2.2M35.4M182.81K
2026-05-156.18%2.2M35.4M188.78K
2026-04-306.56%2.3M35.4M212.29K
2026-04-155.92%2.1M35.4M221.28K
2026-03-316.16%2.1M34.1M260.38K
2026-03-135.25%1.8M34.1M243.43K
2026-02-274.38%1.5M34.1M181.32K
2026-02-133.99%1.4M34.1M185.90K
2026-01-303.90%1.3M33.7M159.57K
2026-01-153.36%1.1M33.7M145.27K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.000.00-0.000.00---
call5.000.000.002.00-10.000.00---
call7.500.000.000.20-67.000.00---
call10.000.000.000.05-2.000.00---
put2.500.000.000.00-0.000.00---
put5.000.000.000.20-41.000.00---
put7.500.000.000.00-0.000.00---
put10.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-10-28SEC
2026-10-228-KCurrent report2026-10-22SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-098-KCurrent report2026-10-09SEC
2026-10-078-KCurrent report2026-10-07SEC
2026-09-048-KCurrent report2026-09-03SEC
2026-09-038-KCurrent report2026-09-01SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-178-KCurrent report2026-08-14SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-168-KCurrent report2026-07-16SEC
2026-07-158-KCurrent report2026-07-15SEC
2026-05-19EFFECTEffectiveness filing by commission orderSEC
2026-05-158-KCurrent report2026-05-13SEC
2026-05-15CORRESPSEC
2026-05-15UPLOADUpload SubmissionSEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-12S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-168-KCurrent report2026-04-16SEC
2026-04-148-KCurrent report2026-04-14SEC
2026-04-018-KCurrent report2026-04-01SEC
2026-03-278-KCurrent report2026-03-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FIL Ltd6.56%
GAGNON SECURITIES LLC5.61%
ROYCE & ASSOCIATES LP3.32%
Timelo Investment Management Inc.3.07%
Gagnon Advisors, LLC2.63%
LETKO, BROSSEAU & ASSOCIATES INC2.56%
Rosalind Advisors, Inc.2.28%
Z3 Capital Partners, LLC2.14%
MMCAP International Inc. SPC1.85%
ARDSLEY ADVISORY PARTNERS LP1.58%

Funds

Fund% owned
ROYCE MICRO-CAP TRUST, INC.2.04%
First Eagle Small Cap Opportunity Fund1.10%
Royce Micro-Cap Fund0.95%
Royce Capital Fund - Micro-Cap Portfolio0.31%
Fidelity Nasdaq Composite Index Fund0.07%
Invesco NASDAQ Future Gen 200 ETF0.04%
The Canadian Small Company Series0.01%
INTERNATIONAL CORE EQUITY 2 PORTFOLIO0.01%
Dimensional International Core Equity 2 ETF0.01%
Dimensional International Small Cap ETF0.00%

OakChart. PROF. Cached 15 minutes.

Some panels did not load: insider.